NCT00563160Unknown2 期
Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery
Hospital Authority, Hong Kong1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2005年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- pathological response rate
研究概览
简要总结
To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven, newly diagnosed primary bronchogenic non-small cell lung cancer
- •Measurable or evaluable tumour on chest X-ray or CT scan.
- •No multiple ipsilateral or contralateral parenchymal tumours
- •Stage I(exceptT1N0),II,IIIa disease as shown by PET-CT
排除标准
- 未提供
结局指标
主要结局
pathological response rate
时间窗: 12 months
次要结局
- quality of life measurements(18 months)
- progression-free survival(18 months)
- overall survival(18 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic CarcinomaResectable Pancreatic CarcinomaNCT01333124National Cancer Center, Korea23
已完成
2 期
Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic CarcinomaPancreatic Carcinoma Non-resectableNCT01593475National Cancer Center, Korea44
Unknown
2 期
A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node MetastasisBiliary Tract CancerNCT01821248Kansai Hepatobiliary Oncology Group25
已完成
2 期
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT00697905Ministry of Health, Malaysia18
终止
2 期
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCNon-Small Cell Lung CancerNCT00960297SCRI Development Innovations, LLC4